Impact of Point-of-Care Testing on the Management of Sexually Transmitted Infections in South Africa: Evidence from the HVTN702 Human Immunodeficiency Virus Vaccine Trial
Clinical Infectious Diseases · 04.03.2023 · 76 (5) · 881-889
DOI: 10.1093/cid/ciac824 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 17.10.2022. Verfasst von Kwabena Asare und 16 weiteren Autor:innen. Beteiligte Einrichtung: Discipline of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa. Hauptthemen laut MEDLINE: Chlamydia Infections, Gonorrhea, HIV Infections, Sexually Transmitted Diseases. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust, NIAID NIH HHS, NIH HHS.
Abstract (Originalsprache)
Background
Alternative approaches to syndromic management are needed to reduce rates of sexually transmitted infections (STIs) in resource-limited settings. We investigated the impact of point-of-care (POC) versus central laboratory–based testing on STI treatment initiation and STI adverse event (STI-AE) reporting.
Methods
We used Kaplan-Meier and Cox regression models to compare times to treatment initiation and STI-AE reporting among HVTN702 trial participants in South Africa. Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT) were diagnosed POC at eThekwini clinic and in a central laboratory at Verulam/Isipingo clinics. All clinics used POC assays for Trichomonas vaginalis (TV) testing.
Results
Among 959 women (median age, 23 [interquartile range, 21–26] years), median days (95% confidence interval [95%CI]) to NG/CT treatment initiation and NG/CT-AE reporting were 0.20 (.16–.25) and 0.24 (.19–.27) at eThekwini versus 14.22 (14.12–15.09) and 15.12 (13.22–21.24) at Verulam/Isipingo (all P < .001). Median days (95%CI) to TV treatment initiation and TV-AE reporting were 0.17 (.12–.27) and 0.25 (.20–.99) at eThekwini versus 0.18 (.15–.2) and 0.24 (.15–.99) at Verulam/Isipingo (all P > .05). Cox regression analysis revealed that NG/CT treatment initiation (adjusted hazard ratio [aHR], 39.62 [95%CI, 15.13–103.74]) and NG/CT-AE reporting (aHR, 3.38 [95%CI, 2.23–5.13]) occurred faster at eThekwini versus Verulam/Isipingo, while times to TV treatment initiation (aHR, 0.93 [95%CI, .59–1.48]) and TV-AE reporting (aHR, 1.38 [95%CI, .86–2.21]) were similar.
Conclusions
POC testing led to prompt STI management with potential therapeutic and prevention benefits, highlighting its utility as a diagnostic tool in resource-limited settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Discipline of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa.
- Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.
- Health Economics and HIV and AIDS Research Division, University of KwaZulu-Natal, Durban, South Africa.
- Department of Internal Medicine, College of Medicine, Howard University, Washington, District of Columbia, USA.
- Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxfordshire, United Kingdom.
- HIV and Other Infectious Diseases Research Unit, South African Medical Research Council, Cape Town, South Africa.
ORCID-Profile: Kwabena Asare
Förderung
- Wellcome Trust
- NIAID NIH HHS
- NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
- Bill and Melinda Gates Foundation
- US Public Health Service
- South African Medical Research Council
Zitieren
APA
Asare, K., Andine, T., Naicker, N., Dorward, J., Singh, N., Spooner, E., Andriesen, J., Osman, F., Ngcapu, S., Vandormael, A., Mindel, A., Abdool Karim, S. S., Bekker, L. G., Gray, G., Corey, L., Tomita, A., & Garrett, N. (2023). Impact of Point-of-Care Testing on the Management of Sexually Transmitted Infections in South Africa: Evidence from the HVTN702 Human Immunodeficiency Virus Vaccine Trial. Clinical Infectious Diseases, 76(5), 881-889. https://doi.org/10.1093/cid/ciac824
Vancouver
Asare K, Andine T, Naicker N, Dorward J, Singh N, Spooner E, et al. Impact of Point-of-Care Testing on the Management of Sexually Transmitted Infections in South Africa: Evidence from the HVTN702 Human Immunodeficiency Virus Vaccine Trial. Clinical Infectious Diseases. 2023;76(5):881-889. doi:10.1093/cid/ciac824
BibTeX
@article{Asare2023,
author = {Asare, Kwabena and Andine, Tsion and Naicker, Nivashnee and Dorward, Jienchi and Singh, Nishanta and Spooner, Elizabeth and Andriesen, Jessica and Osman, Farzana and Ngcapu, Sinaye and Vandormael, Alain and Mindel, Adrian and Abdool Karim, Salim S and Bekker, Linda-Gail and Gray, Glenda and Corey, Lawrence and Tomita, Andrew and Garrett, Nigel},
title = {Impact of Point-of-Care Testing on the Management of Sexually Transmitted Infections in South Africa: Evidence from the HVTN702 Human Immunodeficiency Virus Vaccine Trial},
journal = {Clinical Infectious Diseases},
year = {2023},
volume = {76},
number = {5},
pages = {881--889},
doi = {10.1093/cid/ciac824}
}
EUVIMED